Cargando…

PB2076: GUIZHI FULING CAPSULE REGULATES AUTOPHAGY TO INTERFERE WITH BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY

Detalles Bibliográficos
Autores principales:	Fu, Jiaqi, Cui, Xing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429222/ http://dx.doi.org/10.1097/01.HS9.0000975100.59813.9b

Ejemplares similares

PB2076: PEDIATRIC-TYPE FOLLICULAR LYMPHOMA - A NEW PARADIGM IN DIAGNOSIS?
por: Fonseca, L., et al.
Publicado: (2022)

Guizhi Fuling Capsule Exhibits Antidysmenorrhea Activity by Inhibition of Cyclooxygenase Activity
por: Zheng, Weiran, et al.
Publicado: (2020)

Metabolomics Study of Guizhi Fuling Capsules in Rats With Cold Coagulation Dysmenorrhea
por: Zhang, Yu, et al.
Publicado: (2021)

The Effects of Guizhi Fuling Capsule Drug Serum on Uterine Leiomyoma Cells and Its Mechanism
por: Shen, Qi, et al.
Publicado: (2016)

Deciphering the Pharmacological Mechanisms of Guizhi-Fuling Capsule on Primary Dysmenorrhea Through Network Pharmacology
por: Zhang, Siqin, et al.
Publicado: (2021)

Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteers
por: Zhong, Yun-Xi, et al.
Publicado: (2016)

The Multiple Pharmacologic Functions and Mechanisms of Action of Guizhi Fuling Formulation
por: Gao, Jie, et al.
Publicado: (2022)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

Traditional Chinese medicine prescription Guizhi Fuling Pills in the treatment of endometriosis
por: Wang, Xin, et al.
Publicado: (2021)

PB2493: PERIPHERAL NEUROPATHY A HIDDEN CAUSE FOR PAIN IN GAUCHER DISEASE.A CASE REPORT AND REVIEW OF LITERATURE
por: Abdel Gwad Tantawy, Azza, et al.
Publicado: (2023)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

PB2082: BONE MORPHOGENIC PROTEIN-6 PROMOTES THE PROLIFERATION AND INHIBITS APOPTOSIS IN MULTIPLE MYELOMA
por: Fu, Jiaqi, et al.
Publicado: (2023)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

Evaluation of Anti-Inflammatory Components of Guizhi Fuling Capsule, an Ancient Chinese Herbal Formula, in Human Umbilical Vein Endothelial Cells
por: Zheng, Yuzhong, et al.
Publicado: (2020)

PB1953: ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS.
por: Eleonora, M., et al.
Publicado: (2022)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022)

Efficacy of Guizhi Fuling Wan for primary dysmenorrhea: protocol for a randomized controlled trial
por: Du, Yun, et al.
Publicado: (2021)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA
por: Nameera, Rahmathullah Sulaimankutty, et al.
Publicado: (2023)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

PB2405: BAICALIN MODULATES INTESTINAL FLORA TO TREAT AGVHD
por: Yang, Jingrong, et al.
Publicado: (2023)

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
por: Elsabah, H., et al.
Publicado: (2022)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids
por: Zeng, Liuting, et al.
Publicado: (2017)

Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
por: Wang, Haoxian, et al.
Publicado: (2021)

Correction to: Efficacy of Guizhi Fuling Wan for primary dysmenorrhea: protocol for a randomized controlled trial
por: Du, Yun, et al.
Publicado: (2021)

PB2198: EFFECTS OF NOVEL CORONAVIRUS VACCINATION ON THE COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS FROM HEALTHY DONORS
por: Wang, Z., et al.
Publicado: (2022)

PB2036: PERIPHERAL BLOOD CYTOPENIA, AN EARLY INDICATOR OF INBORN ERRORS OF IMMUNITY
por: Chapanduka, Zivanai Cuthbert, et al.
Publicado: (2023)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB2037: RESULTS FROM PIMMS, A UK MYELOMA RESEARCH ALLIANCE (UKMRA) STUDY OF OUTCOMES AND TOXICITY OF PANOBINOSTAT WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MYELOMA IN A REAL WORLD SETTING
por: Waters, J., et al.
Publicado: (2022)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
por: Girnius, Saulius K., et al.
Publicado: (2023)

PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT
por: Faulkner, L., et al.
Publicado: (2022)

PB1835: SHENGMA BIEJIA DECOCTION,A TRADITIONAL CHINESE MEDICINE PRESCRIPTION,INDUCES LEUKEMIA CELLS MITOCHONDRIAL AUTOPHAGY VIA MITOCHONDRIAL DIVISION WAY.
por: Si, Yuping, et al.
Publicado: (2023)

PB1705: THE HISTONE MODIFIER SETD6 IS EPIGENETICALLY REGULATED IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND INTERFERES WITH PROLIFERATION AND GENE EXPRESSION
por: Veselinova, Yoana, et al.
Publicado: (2023)

Add-on effect of Guizhi Fuling formula to mifepristone for endometriosis: A meta-analysis of randomized controlled trials
por: Meng, Wenbin, et al.
Publicado: (2019)

Fuling-Guizhi Herb Pair in Coronary Heart Disease: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
por: Duan, Bailu, et al.
Publicado: (2020)

Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis
por: Wang, Haoxian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_31rf7d5tdrb16l2t3b19dh8e74